<DOC>
	<DOCNO>NCT00684216</DOCNO>
	<brief_summary>This trial study effect quality life time second progression sequence endocrine therapy-capecitabine versus sequence capecitabine-endocrine treatment . It anticipate time study ( time randomization discontinuation second treatment sequence ) similar arm study . The quality life period , however , could better patient group receive effective first agent sequence . If prof true , conventional wisdom endocrine therapy continue endocrine option remain , must abandon .</brief_summary>
	<brief_title>Second-line Endocrine Treatment Followed Capecitabine Versus Capecitabine Followed Endocrine Treatment Patients With Metastatic ER Positive Breast Cancer</brief_title>
	<detailed_description>This randomized phase II/II study . Patients randomized sequence capecitabine-hormonal therapy versus hormonal therapy- capecitabine . At progression patient receive protocol treatment ( e.g . patient randomized capecitabine , progression treatment switch hormonal treatment ) .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>1 . Written informed consent . 2 . Proven infiltrate breast cancer distant metastasis inoperable locally advanced disease . 3 . Positive estrogen receptor ( â‰¥ 10 % positive nuclei immunohistochemistry ) . Progesterone HER2 neu receptor know . 4 . Progressive disease first line hormonal therapy ( either tamoxifen aromatase inhibitor ) metastatic inoperable locally advanced disease . Simultaneous use LHRH analog allow . OR Recurrence disease ( M1 ) adjuvant hormonal therapy ( either tamoxifen aromatase inhibitor ) . 5 . No prior chemotherapy metastatic disease 6 . Willing able participate Quality Life investigation 1 . Other malignancy except carcinoma situ , unless malignancy treat 5 year ago curative intent without use chemotherapy radiation therapy . 2 . Pregnancy breast feeding woman . 3 . Contraindications use capecitabine 4 . Known CNS metastasis</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>metastatic</keyword>
	<keyword>ER positive</keyword>
	<keyword>PD during/after first line hormonal treatment</keyword>
</DOC>